Researchers at the University of Nottingham developed a modular platform for RNA delivery using supramolecular chemistry. This content is an AI-generated, fully rewritten summary based on a published ...
Corporate compliance isn’t just about avoiding fines; it’s an opportunity to shape culture, partnerships, and everyday decision-making Erik Vaessen on the costs, complexities, and technologies shaping ...
Review examines how PAT, model-based control, reinforcement learning, and digital twins could maintain product quality from perfusion culture through downstream purification ...
The company says the acquisition will strengthen downstream antibody manufacturing and help biopharma customers scale more efficiently. Acquisition adds over 50 employees and technical expertise in ...
WashU Medicine-developed WU-CART-007 has received Breakthrough Therapy designation after early clinical results in relapsed or refractory T-cell leukemias and lymphomas. This content is an ...
The path from preclinical research to API drug commercialization is fraught with risk and complexity, with thousands of compounds narrowing down to a single drug suitable for patient use. The intense ...
Cell lysis is often seen as just another step in the upstream workflow for gene therapy production, but it’s anything but routine. This moment of breaking open cells determines not only how much ...
For centuries, healers across Africa have relied on medicinal plants to treat everything from infections to chronic conditions. Their knowledge, passed down through generations, remains central to ...
Moderna has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for ...
Pharmaceutical formulation is undergoing a quiet revolution, and most of the industry has not caught up yet. We are no longer bound by trial-and-error, or month-long iteration cycles. Thanks to ...
We are all watching the rise of oral, small molecule GLP-1 receptor agonists with justified interest. The promising phase III results of Eli Lilly’s orforglipron has set the pace, and others are ...
Clinical development has always been a complex process, requiring various stakeholders including pharmaceutical and biotech companies, patient groups, clinical research organizations (CROs) and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results